# Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

> **NCT02115048** · PHASE2 · TERMINATED · sponsor: **Translational Research in Oncology** · enrollment: 44 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02115048
- **Lead sponsor:** Translational Research in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Study was completed as per amended protocol. Protocol was amended to close enrollment earlier than initially planned (study continued as per plan).
- **Last updated:** 2019-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115048, "Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*